This panel was previously made commercially available in the U.S. ![]() The molecular test provides results in less than two hours for more than 20 viruses and bacteria that cause common and often serious respiratory infections, including COVID-19, influenza A and B, respiratory syncytial virus (RSV) and rhinovirus. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has achieved CE Mark under the European In‐Vitro Diagnostic Devices Directive (98/79/EC) for its ePlex® Respiratory Pathogen Panel 2 (RP2). 14, 2020 (GLOBE NEWSWIRE) - GenMark Diagnostics, Inc. The rapid, multiplex molecular testing offered by RP2 will be vital this fall and winter, when COVID-19 coincides with flu and other common respiratory infections, helping doctors quickly diagnose and effectively treat seriously ill patients.ĬARLSBAD, Calif., Sept.RP2 provides results in less than two hours for more than 20 viruses and bacteria that cause common respiratory infections with similar symptoms, including COVID-19, influenza A and B, respiratory syncytial virus (RSV) and rhinovirus. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |